江苏森萱医药股份有限公司 证券代码：920946 证券简称：森萱医药 公告编号：2025-100 江苏森萱医药股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 3.会议召开方式：现场投票和网络投票相结合 4.会议召集人：董事会 5.会议主持人：吴玉祥 6.召开情况合法合规的说明： 本次股东会的召集、召开、议案审议符合《公司法》等有关法律、法规及《公 司章程》的规定。 （二）会议出席情况 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 11 月 27 日 2.会议召开地点：南通市崇川区观音山街道青年中路 198 号国城生活广场 A 幢 21 楼会议室 江苏森萱医药股份有限公司 出席和授权出席本次股东会的股东共 6 人，持有表决权的股份总数 321,780,974 股，占公司有表决权股份总数的 75.372956%。 其中通过网络投票参与本次股东会的股东共 3 人，持有表决权的股份总数 12,881,634 股，占公司有表决权股份 ...

江苏世纪同仁律师事务所 关于江苏森营医药股份有限公司 2025 年第三次临时股东会的法律意见书 江苏森萱医药股份有限公司: 2025 年第三次临时股东会法律意见书 森萱医药 由于贵公司本次股东会采取现场投票和网络投票相结合的方式,贵公司在公 告中还对网络投票的投票时间、投票代码、投票议案序号等有关事项做出明确说 明。 - 1 - '根据《公司法》《证券法》和中国证监会《上市公司股东会规则》等法律、 法规和规范性文件以及《公司章程》的规定,本所受贵公司董事会的委托,指派 本所律师出席贵公司 2025年第三次临时股东会,并就本次股东会的召集、召开 程序、出席会议人员资格、召集人资格、表决程序和表决结果的合法有效性出具 法律意见。 为出具本法律意见书,本所律师对本次股东会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关间题进行了必要的核查和验证。 本所律师同意将本法律意见书随贵公司本次股东会决议一并公告,并依法对 本法律意见书承担相应的责任。 本所律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的业 务标准、道德规范和勤勉尽责精神,出具法律意见如下: 一、关于本次股东会的召集、召开程序 1、本次 ...

江苏森萱医药股份有限公司 证券代码：920946 证券简称：森萱医药 公告编号：2025-102 江苏森萱医药股份有限公司 章 程 （2025 年第三次临时股东会审议通过） 二〇二五年十一月 江苏森萱医药股份有限公司 第一章 总则 第一条 为维护江苏森萱医药股份有限公司（以下简称"公司"）、股东、职工 和债权人的合法权益，充分发挥公司党组织的政治核心作用，规范公司的组织和 行为，根据《中国共产党章程》（以下简称"《党章》"）、《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司独立董事管理办法》、《北京证券交易所股票上市规则》、《北京证券交 易所上市公司持续监管办法（试行）》、《北京证券交易所上市公司持续监管指引 第 1 号—独立董事》和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。公司 由江苏森萱医药化工有限公司（注册号：321283000011244）整体变更基础上， 以发起方式设立；在南通市数据局注册登记，取得营业执照，统一社会信用代码： 91321200748720948H。 第三条 公司经全 ...

Summary of Senxuan Pharmaceutical Conference Call Company Overview - Senxuan Pharmaceutical is a leading domestic specialty raw material pharmaceutical company, focusing on chemical raw materials and pharmaceutical intermediates, particularly in the fields of anti-tumor and anti-epileptic drugs, while actively expanding into lithium battery and new material intermediates [2][4][5] Key Financial Performance - In Q3 2025, Senxuan Pharmaceutical reported a net profit growth of approximately 64%, driven by increased overseas market demand and new raw material drug contributions [2][6] - Overseas revenue grew by 13% year-on-year, with gross margin exceeding 48% [2][6] - The company expects net profits for 2025, 2026, and 2027 to be 130 million, 153 million, and 174 million CNY respectively, with corresponding EPS of 0.30, 0.36, and 0.41 CNY per share [4][14][23] Revenue Sources and Margins - Main revenue sources include: - Raw materials: over 60% of revenue, gross margin around 57% [2][9][10] - Pharmaceutical intermediates: 15%-20% of revenue, gross margin approximately 27% [2][9] - Oxygen-containing heterocyclic chemical intermediates: about 25% of revenue, gross margin around 33% [2][9] - The company has a diverse customer base, with the top five customers accounting for only 27% of total sales, indicating low customer concentration [2][11] Long-term Development Strategy - Senxuan Pharmaceutical's long-term strategy includes: 1. Dual-driven approach of exporting raw materials and optimizing product structure to enhance gross margins [7] 2. Annual development and launch of one to two new products, with current projects like ritonavir and succinic acid expected to generate significant revenue [7][8] 3. Integrated supply chain advantages and support from state-owned assets for capacity expansion and mergers [8] Industry Context and Challenges - The pharmaceutical industry faces challenges such as stricter environmental and safety regulations, which may increase industry concentration, benefiting leading companies like Senxuan Pharmaceutical [15] - The company is addressing these challenges by focusing on niche specialty raw materials, enhancing R&D patent barriers, and expanding into overseas markets to mitigate price volatility risks [15] Competitive Advantages - Senxuan Pharmaceutical holds over 20 domestic registration certificates and multiple international certifications, including EU CEP and Australian GMP, enhancing its market competitiveness [13] - It is one of the largest domestic suppliers of dioxolane and dioxane, which are widely used in lithium battery electrolytes and other emerging fields [13] Future Outlook - The global chemical raw material market is expected to grow at an average annual rate of 6% from 2024 to 2032, with China playing a significant role as a major producer and exporter [18][19] - The company plans to increase R&D investments to enhance market share in high-tech products and actively explore overseas markets, which may lead to new growth opportunities [14][23] Conclusion - Senxuan Pharmaceutical is well-positioned for future growth with a solid financial performance, diverse revenue streams, and a strategic focus on R&D and market expansion, despite facing industry challenges [2][4][15][23]

Core Viewpoint - Jiangsu Senxuan Pharmaceutical Co., Ltd., established in 2003, is a leading enterprise in the domestic specialty raw material pharmaceutical sector and one of the first companies listed on the Beijing Stock Exchange [1] Company Overview - The company adheres to the philosophy of "gathering the essence of the world to create timeless medicines" as stated by Chairman Wu Yuxiang during an interview [1] - Senxuan Pharmaceutical is among the first batch of companies to be listed on the National Equities Exchange and Quotations (NEEQ) selective layer [1]

Core Viewpoint - Senxuan Pharmaceutical reported a revenue increase of 5.90% year-on-year for the first three quarters of 2025, driven by improved product quality and service, successful commercialization of new raw materials, and enhanced operational efficiency [1][2] Group 1: Financial Performance - For the first three quarters of 2025, Senxuan Pharmaceutical achieved a revenue of 411 million yuan, a year-on-year increase of 5.90% [1] - The net profit attributable to shareholders for the same period was 104 million yuan, reflecting a year-on-year growth of 13.45% [1] - In the third quarter alone, the company reported a revenue of 150 million yuan, marking a significant year-on-year increase of 29.45% [1] - The net profit for the third quarter was 35.736 million yuan, which is a remarkable year-on-year growth of 64.79% [1] Group 2: Growth Drivers - The revenue growth was attributed to three main factors: improved product quality and service leading to increased market share, successful commercialization of new raw materials, and ongoing internal management optimization [1] - The company plans to ensure long-term stable growth by advancing the overseas registration of both new and existing products, particularly in high-end regulatory markets in Europe and the United States [1] Group 3: R&D and Market Expansion - Research and development expenses decreased by 12.73% year-on-year, primarily due to some projects reaching maturity and reduced investment in early-stage projects [2] - Despite the decrease, the company emphasized that its commitment to R&D remains strong, focusing on high-potential therapeutic areas such as antiviral, anti-tumor, and anti-epileptic treatments [2] - The subsidiary, Luhua Senxuan, has successfully entered markets in engineering plastics, fibers, and pharmaceuticals, with plans to expand into new applications and markets, including Russia and Southeast Asia [2] - An industry standard for 1,3-Dioxolane, led by Luhua Senxuan, is set to be implemented in March 2026, which is expected to enhance the brand influence in the new materials sector [2]

Core Insights - Jiangsu Senxuan Pharmaceutical Co., Ltd. is a leading enterprise in the domestic specialty raw materials pharmaceutical sector and was among the first to be listed on the Beijing Stock Exchange [1][7] - The company emphasizes innovation and R&D as its core strategy, maintaining a high level of investment in research and development [3][4] R&D and Innovation - Senxuan Pharmaceutical has established multiple provincial R&D platforms and has capabilities across various stages of drug development, achieving international advanced levels in several product technical indicators [3] - The company invested nearly 20 million yuan in R&D in the first three quarters, representing about 4.85% of its revenue, and has made breakthroughs in green synthesis processes and other areas [3][4] Financial Performance - In the first three quarters, the company achieved revenue of 411 million yuan, a year-on-year increase of 5.9%, and a net profit of 104 million yuan, up 13.45% year-on-year [5] - The company has maintained a stable cash dividend policy, distributing approximately 60 million yuan to shareholders, reflecting confidence in future growth [5] Market Position and Growth Strategy - The company is focused on consolidating its market position and creating new growth points through overseas market expansion and new product sales [5] - Future strategies include continuous R&D investment, optimizing production processes, and exploring strategic investments in pet medicine and medical aesthetics [6] Impact of Listing on the Beijing Stock Exchange - Listing on the Beijing Stock Exchange has significantly enhanced the company's brand credibility and industry influence, improving its reputation among clients and attracting high-quality management talent [7] - The funds raised from the IPO are being used to advance projects that will alleviate capacity bottlenecks and support larger market orders [7][8]

江苏森萱医药股份有限公司 证券代码：920946 证券简称：森萱医药 公告编号：2025-099 江苏森萱医药股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 活动时间：2025 年 11 月 12 日 活动地点：公司通过中证路演中心（https://www.cs.com.cn/roadshow/） 采用网络远程的方式召开业绩说明会。 参会单位及人员：通过网络方式参与公司 2025 年第三季度报告业绩说明会 的投资者。 上市公司接待人员：公司董事长吴玉祥先生；公司副董事长、总经理袁拥军 先生；公司董事会秘书、财务负责人朱狮章先生。 三、 投资者关系活动主要内容 江苏森萱医药股份有限公司 江苏森萱医药股份有限公司 问题 1：公司经营内容增加"危险化学品"，是否涉及新业务？ 回答：根据公司日常经营业务发展需要，母公司的经营 ...

Core Points - The Shanghai Composite Index closed at 4017.94 points, above the six-month moving average, with a gain of 0.44% [1] - The total trading volume of A-shares reached 12,733.37 million yuan [1] - A total of 113 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] Summary of Key Stocks - **Top Performers**: - Senxuan Pharmaceutical (证券代: 920946) increased by 6.14% with a deviation rate of 5.96% - Huina Technology (证券代: 300609) rose by 9.74% with a deviation rate of 5.79% - Xiangyuan Cultural Tourism (证券代: 600576) gained 9.99% with a deviation rate of 5.54% [1] - **Stocks with Smaller Deviations**: - Zhongji Huanan (证券代: 300609) and Benlang New Materials (证券代: 920914) have just crossed the six-month moving average with minor deviation rates [1] Additional Notable Stocks - Other stocks with significant performance include: - Shunling Environment (证券代: 301018) with a 6.66% increase and a deviation rate of 4.47% - Taihe New Materials (证券代: 002254) up by 4.66% with a deviation rate of 4.27% [1] - Stocks with lower performance but still above the six-month line include: - Hongquan Technology (证券代: 688288) with a 7.82% increase and a deviation rate of 2.51% - Zhenxin Technology (证券代: 300101) increased by 3.16% with a deviation rate of 2.41% [2]

Core Viewpoint - The recent fluctuations in the Shanghai Composite Index around the 4000-point mark have led to increased adjustments in stock ratings by brokerages, with a total of 23 stocks upgraded and 40 downgraded since the end of October. The electronic sector saw the highest number of upgrades, while consumer and pharmaceutical sectors experienced significant divergence in ratings [1]. Group 1: Stock Rating Adjustments - A total of 23 stocks have had their ratings upgraded by brokerages, while 40 stocks have been downgraded [1]. - The electronic sector had the most stocks with upgraded ratings, indicating strong institutional interest [1]. - Significant rating divergence was observed in the consumer and pharmaceutical sectors, suggesting varied outlooks among analysts [1]. Group 2: Future Market Outlook - Multiple brokerages have begun releasing their investment strategies for 2026, with a generally positive outlook for A-shares in the coming year [1]. - CITIC Securities noted that the Chinese capital market is gradually transitioning to a mature market, predicting a "slow bull" market with lower volatility during the 14th Five-Year Plan period [1].